Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 9/20 | 0.67 |
| ▸ | MMP9 | P14780 | 9/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.61 |
| ▸ | BRS3 | P32247 | 4/20 | 0.60 |
| ▸ | NMBR | P28336 | 2/20 | 0.60 |
| ▸ | AIMP2 | Q13155 | 1/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22500968 | 1.00 | MMP2 (0.67) | MMP2MMP9KMT2ANR3C1BRS3 | |
| SCHEMBL22500563 | 0.97 | KMT2A (0.68) | MMP2MMP9KMT2ANR3C1BRS3 | |
| SCHEMBL22500564 | 0.97 | KMT2A (0.68) | MMP2MMP9KMT2ANR3C1BRS3 | |
| SCHEMBL22500398 | 0.95 | MMP9 (0.65) | MMP2MMP9KMT2ANR3C1BRS3 | |
| SCHEMBL22500400 | 0.95 | MMP9 (0.65) | MMP2MMP9KMT2ANR3C1BRS3 | |
| SCHEMBL22500341 | 0.94 | KMT2A (0.62) | MMP2MMP9KMT2ANR3C1BRS3 | |
| SCHEMBL22500342 | 0.94 | KMT2A (0.62) | MMP2MMP9KMT2ANR3C1BRS3 | |
| SCHEMBL22500314 | 0.93 | MMP2 (0.67) | MMP2MMP9KMT2ANR3C1NMBR | |
| SCHEMBL22500315 | 0.93 | MMP2 (0.67) | MMP2MMP9KMT2ANR3C1NMBR | |
| SCHEMBL22500474 | 0.93 | KMT2A (0.63) | MMP2MMP9KMT2ANR3C1BRS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220204497-A1 | NOVEL COMPOUND HAVING ANTICANCER ACTIVITY, AND METHOD FOR PRODUCING SAME | DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2022-06-30 | — | — | US | claimed |
| EP-3939968-A1 | NOVEL COMPOUND HAVING ANTICANCER ACTIVITY, AND METHOD FOR PRODUCING SAME | Medicinal Bioconvergence Research Center (KR) | 2022-01-19 | — | — | EP | claimed |
| US-20220204497-A1 | NOVEL COMPOUND HAVING ANTICANCER ACTIVITY, AND METHOD FOR PRODUCING SAME | DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2022-06-30 | — | — | US | disclosed |
| EP-3939968-A1 | NOVEL COMPOUND HAVING ANTICANCER ACTIVITY, AND METHOD FOR PRODUCING SAME | Medicinal Bioconvergence Research Center (KR) | 2022-01-19 | — | — | EP | disclosed |
| WO-2020204548-A1 | NOVEL COMPOUND HAVING ANTICANCER ACTIVITY, AND METHOD FOR PRODUCING SAME | 재단법인 의약바이오컨버젼스연구단 | 2020-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204497-A1 | NOVEL COMPOUND HAVING ANTICANCER ACTIVITY, AND METHOD FOR PRODUCING SAME | TPX2, AIMP2, CDYL2 | MMP2 3511/4885MMP9 1778/4885KMT2A 1721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.